Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTROCELL: Allogeneic vs Autologous MSCs in Knee Osteoarthritis
NCT05086939Phase 3Active, not recruiting
- Sponsor
- Fundación Instituto de Ciencias de la Salud de Castilla y León
- Start
- May 2021
- Primary completion
- May 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL), autologous mesenchymal stromal cells in knee osteoarthritis (OA), sponsored by Fundación Instituto de Ciencias de la Salud de Castilla y León. Started May 2021; status: active, not recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)autologous mesenchymal stromal cells
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05086939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086939.